Business context and reporting period
GSK plc’s Form 20-F is an annual report for the fiscal year ended December 31, 2018, filed March 15, 2019. The filing incorporates much of the 2018 Annual Report by reference. GSK operates across Pharmaceuticals, Vaccines and Consumer Healthcare and reports under IFRS as issued by the IASB. Although the request metadata says “2018 Q4,” this is an annual filing, not a standalone quarterly report.
The supplied filing text contains detailed operating-review material for 2017, alongside a reconciliation of 2018 results. It does not provide a clear 2018 revenue figure or enough 2018 operating detail to assess segment performance fully.
Financial performance and position
Amounts are in £ millions unless stated otherwise. Adjusted results are non-IFRS measures; they should be considered alongside, not instead of, IFRS results.
| Metric | 2018 | 2017 | Change |
|---|---|---|---|
| Revenue / turnover | Not clear in supplied text | Not used here | Not determinable |
| Total gross profit | 20,580 | Not clear in supplied reconciliation | Not determinable |
| Total operating profit | 5,483 | 4,087 | +34% |
| Total profit before tax | 4,800 | 3,525 | +36% |
| Total profit after tax | 4,046 | 2,169 | +87% |
| Total earnings per share | 73.7p | 31.4p | +135% |
| Adjusted operating profit | 8,745 | 8,568 | +2% |
| Adjusted profit before tax | 8,078 | 7,924 | +2% |
| Adjusted profit after tax | 6,543 | 6,257 | +5% |
| Adjusted earnings per share | 119.4p | 111.8p | +7% |
| Total net finance costs | 717 | 669 | +7% |
The sizeable increase in total profit and EPS should be read alongside the substantial adjusting items in both years. The reconciliation identifies 2018 transaction-related adjustments of £1,974 million and major restructuring charges of £813 million, among other items. For 2017, the reconciliation includes £1,599 million of transaction-related adjustments and £1,060 million of major restructuring charges.
The supplied text does not provide clear 2018 cash flow, cash balances, borrowings, net debt, liquidity ratios, tax rate, or dividend totals. It also does not provide a clear 2018 revenue figure, so 2018 margins cannot be calculated from this text.
Material changes and business developments
- Adjusted operating profit increased modestly, while total operating profit rose more sharply; the reconciliation shows that reported results include significant adjusting items.
- GSK and Pfizer signed an agreement in December 2018 to combine their consumer healthcare businesses. Subject to conditions and approvals, Pfizer would receive a 32% interest and GSK would retain 68% and control.
- GSK completed the Novartis Consumer Healthcare put-option transaction in June 2018 for US$13 billion, acquiring control of the remaining shares in that business, according to the filing.
- The detailed segment sales discussion in the supplied text is for 2017 and should not be treated as 2018 performance. It describes growth in HIV and newer respiratory products and vaccines, offset in part by declines in older products and pricing pressure.
Outlook, risks and unusual items
Management’s stated 2019 outlook is for adjusted EPS to decline by 5%–9% at constant exchange rates. The filing attributes this outlook to the expected impact of the Tesaro acquisition and investment in its products and pipeline, other recently announced transactions, and approval of a substitutable generic competitor to Advair in the US. GSK did not provide guidance for total results, citing difficulty forecasting items such as intangible-asset impairments and future fair-value movements in contingent consideration and put options.
Key risks include product safety and quality, regulatory compliance, litigation and government investigations, pricing and generic competition, R&D and patent outcomes, supply continuity, cybersecurity, privacy, tax and treasury exposures, and third-party oversight. The filing also highlights Brexit-related supply-chain contingency planning and ongoing government investigations regarding China and other operations.
The proposed Pfizer transaction carries execution and approval risks. It could be delayed, modified or fail to complete; regulatory remedies or divestitures could reduce anticipated benefits. If specified conditions are not met, GSK may owe Pfizer a US$900 million termination fee. Integration, transaction costs, indemnities, financing and the timing or feasibility of a later separation are additional uncertainties.
Deloitte gave an unqualified opinion on the 2018 IFRS financial statements and concluded that internal control over financial reporting was effective at year-end. The filing notes that its estimates and forward-looking statements involve uncertainty.
Important facts for investors to verify
- Consult the complete 2018 Annual Report incorporated by reference for revenue, segment results, cash flow, debt, liquidity, tax, dividend and balance-sheet figures not clear in the supplied text.
- Reconcile total and adjusted performance, particularly the scale, cash effects and recurrence of transaction, restructuring, legal and other adjusting items.
- Track the Pfizer Consumer Healthcare transaction’s approvals, conditions, potential remedies, integration costs, expected benefits and potential termination-fee exposure.
- Assess the commercial and financial impact of the US generic competitor to Advair and the assumptions underlying 2019 adjusted EPS guidance.
- Review legal proceedings, government investigations, contingent consideration and put-option valuations, and related cash obligations in the full notes.